PharmaNutra SpA: Strong Growth Potential and Strategic Expansion Drive Buy Rating

Intermonte analyst Giorgio Tavolini maintained a Buy rating on PharmaNutra SpA (PHN – Research Report) yesterday and set a price target of €84.00.

Giorgio Tavolini has given his Buy rating due to a combination of factors that highlight PharmaNutra SpA’s strong performance and growth potential. The company reported impressive first-quarter results with double-digit revenue growth, driven by robust international sales and a solid domestic market presence. Despite incurring extraordinary costs to expand new business lines, particularly in the USA and Spain, the company’s EBITDA margin remained stable, reflecting effective cost management.
Furthermore, PharmaNutra’s key product lines, such as Sideral® and Apportal®, have shown significant growth, reinforcing their market leadership. The company’s strategic initiatives, including its US expansion plan and ongoing R&D efforts, are expected to drive future growth. Tavolini also notes the potential for substantial sales increases in the US and China over the next few years, which could significantly boost the stock’s value. With a target price offering a 60% upside, Tavolini believes the market will soon recognize PharmaNutra’s long-term growth story.

In another report released yesterday, TP ICAP MIDCAP also maintained a Buy rating on the stock with a €74.00 price target.